Cargando…

Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2–Amplified Gastric Cancer Patient–Derived Cell Model()

BACKGROUND: FGFR2 amplification is associated with aggressive gastric cancer (GC), and targeted drugs have been developed for treatment of GC. We evaluated the antitumor activity of an FGFR inhibitor in FGFR2-amplified GC patients with peritoneal carcinomatosis. METHODS: Two GC patients with FGFR2 a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Jiryeon, Kim, Hee Kyung, Bang, Heejin, Kim, Seung Tae, Kim, Sun Young, Park, Se Hoon, Lim, Ho Yeong, Kang, Won Ki, Lee, Jeeyun, Kim, Kyoung-Mee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430153/ https://www.ncbi.nlm.nih.gov/pubmed/28501555 http://dx.doi.org/10.1016/j.tranon.2017.03.001

Ejemplares similares

The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
por: Na, Yu Ran, et al.
Publicado: (2021)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

In situ imaging of quantum dot-AZD4547 conjugates for tracking the dynamic behavior of fibroblast growth factor receptor 3
por: Hwang, Gyoyeon, et al.
Publicado: (2017)

Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer
por: Chang, Jinjia, et al.
Publicado: (2014)

In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosis
por: Santorelli, Sara, et al.
Publicado: (2021)

Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs
por: Cho, Hanna, et al.
Publicado: (2021)

Activity of fibroblast growth factor receptor inhibitors TKI258, ponatinib and AZD4547 against TPR-FGFR1 fusion
por: Qiu, Xu-Hua, et al.
Publicado: (2017)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Targeted Inhibition of Fibroblast Growth Factor Receptor 1-GLI Through AZD4547 and GANT61 Modulates Breast Cancer Progression
por: Riaz, Syeda Kiran, et al.
Publicado: (2021)

Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2022)

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
por: Saka, Hideo, et al.
Publicado: (2017)

Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
por: Cho, Junhun, et al.
Publicado: (2017)

Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
por: Liang, Donglou, et al.
Publicado: (2017)

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
por: Kim, Seung Tae, et al.
Publicado: (2021)

Development of mesenchymal subtype gene signature for clinical application in gastric cancer
por: Lee, Jeeyun, et al.
Publicado: (2017)

MerTK is a novel therapeutic target in gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2015)

Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer
por: Jung, Ki Sun, et al.
Publicado: (2017)

Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation
por: Lee, Taehyang, et al.
Publicado: (2018)

A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment
por: Kang, Jinho, et al.
Publicado: (2019)

Sulfated polysaccharide of Sepiella maindroni ink targets Akt and overcomes resistance to the FGFR inhibitor AZD4547 in bladder cancer
por: Shan, Liping, et al.
Publicado: (2019)

Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
por: Coombes, R. C., et al.
Publicado: (2023)

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
por: Kwon, Minsuk, et al.
Publicado: (2022)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Dysregulated miRNA in a cancer-prone environment: A study of gastric non-neoplastic mucosa
por: Kim, Binnari, et al.
Publicado: (2020)

FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
por: Zhao, Qingxia, et al.
Publicado: (2017)

AZD4547 Attenuates Lipopolysaccharide-Induced Acute Kidney Injury by Inhibiting Inflammation: The Role of FGFR1 in Renal Tubular Epithelial Cells
por: Chen, Xuemei, et al.
Publicado: (2020)

The Impact of Concomitant Genomic Alterations on Treatment Outcome for Trastuzumab Therapy in HER2-Positive Gastric Cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

MicroRNA Expression Profiles in Gastric Carcinogenesis
por: Hwang, Jinha, et al.
Publicado: (2018)

Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020)

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy
por: Kim, Seung Tae, et al.
Publicado: (2017)

The Clinical Impact of c-MET Over-Expression in Advanced Biliary Tract Cancer (BTC)
por: Heo, Mi Hwa, et al.
Publicado: (2017)

Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
por: Kim, Hana, et al.
Publicado: (2021)

High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations
por: Maeng, Chi Hoon, et al.
Publicado: (2012)

Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer
por: Kim, Jinchul, et al.
Publicado: (2020)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

MerTK inhibition by RXDX-106 in MerTK activated gastric cancer cell lines
por: Kim, Jung Eun, et al.
Publicado: (2017)

RRAD expression in gastric and colorectal cancer with peritoneal carcinomatosis
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)

The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors
por: Kim, Hana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6meecufpck6vtg1287lbp85n8b